The media could not be loaded, either because the server or network failed or because the format is not supported.

Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO), the kings of the titanic weight-loss drugs market, might have a problem on their hands. After reporting their third-quarter earnings, shares of both ...

The demand for weight loss drugs like Ozempic and Wegovy has led to a flood of fake drugs hitting the market. However, these ...

Analyzing H&H's Q3 results and investment strategy in the healthcare industry, highlighting undervaluation and raising the ...

A flood of dangerous counterfeit drugs is pouring into the U.S., including deadly fake versions of popular weight-loss drugs ...

A simple online search for semaglutide, the active ingredient in Ozempic or Wegovy, can lead consumers down a rabbit hole of ...

In the study, 33.4% of patients taking Wegovy were admitted, compared to about 37% in the placebo cohort. Use of the weight loss drug was also linked to shorter hospital stays. Eli Lilly and Novo ...

Popular weight-loss drugs are helping some runners lose weight and crush PRs. Experts have some real concerns.

No matter how much she ate, she never felt satisfied. But after starting a non-FDA approved GLP-1 agonist—an injectable drug ...